FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). (Q40228769)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Michael C. Heinrich

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

M M Schittenhelm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

K W H Yee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

L McGreevey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

A D Haley

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

A Town

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

D J Griffith

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

T Bainbridge

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

R M Braziel

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

A-M O'Farrell

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

J M Cherrington

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

14 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

2008-2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

KIT mutations are common in testicular seminomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

7 January 2021

Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

7 January 2021

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

7 January 2021

Hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

7 January 2021

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

7 January 2021

Novel FLT3 point mutation in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404374

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990784%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

30 December 2019

1046578137

0 references

1 reference